CareLit Fachartikel

Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor

N.N. · Nervenheilkunde · 2020 · Heft S 01 S 01 · S. S2-S24

Dokument
1210268
CareLit-ID
Jahr
2020
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Nervenheilkunde
Autor:innen
N.N.
Ausgabe
Heft S 01 S 01 / 2020
Jahrgang 39
Seiten
S2-S24
Erschienen: 2020-05-01 00:00:00
ISSN
0722-1541

Zusammenfassung

ZUSAMMENFASSUNG Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selecti…

Schlagworte

Calcitonin Gene-Related Peptide Antibodies Calcitonin Nervenheilkunde